Table 1.
Overview of HIF-1-mediated mechanisms in drug resistance
Resistance phenotype | Cancer/Cell type | Resistant chemotherapy drug | Molecular basis | Reference |
---|---|---|---|---|
Overexpression of drug efflux proteins | Colon cancer cells | 5-Fluorouracil | MDR1/P-gp | [26] |
Overexpression of drug efflux proteins | Ovarian carcinoma cells | Estramustine | ABCA2 | [27] |
Overexpression of drug efflux proteins | Lung adenocarcinoma cells | Adriamycin | P-gp | [28] |
Apoptosis inhibition | Breast cancer cells | Paclitaxel | Caspases 3, 8, 10, and Bak | [29] |
Apoptosis inhibition | Colon cancer cells | Etoposide and oxaliplatin | Bid and Bax | [30] |
Apoptosis inhibition | Gastric cancer cells | 5-Fluorouracil and cisplatin | p53 and NF-kB | [31] |
Apoptosis inhibition | Human melanoma cells | Not mentioned | P53 and TRP2 | [88] |
Autophagy induction | HeLa cells | N-(4-Hydroxypheny) retinamide (4-HPR) | Beclin1 | [32] |
Autophagy induction | Gastric cancer cells | Vincristine | miR-23b-3p, ATG12, and HMGB2 | [33] |
Autophagy induction | Colon cancer cells | Cryptotanshinone Dihydrotanshinone | p53 | [34] |
DNA damage inhibition | Mouse embryonic fibroblasts | Etoposide | DNA–PKcs and Ku80 | [35] |
DNA damage inhibition | Breast and liver cancer cells | Taxol and etoposide | TMEM45A | [36] |
Mitochondrial activity | Human leukemia cell line (HL-60) human lymphoma cell line (Raji) | Doxorubicin and ara-c | BAD | [37] |
Mitochondrial activity | Renal carcinoma cells | Not mentioned | VHL | [38] |
Mitochondrial activity | Oral squamous cell carcinoma cells | 5-Fluorouracil and cisplatin | Cytochrome, Akt, and ERK | [39] |
P53 | Non-small-cell lung cancer cells | Cisplatin | HIF-1α and BAX | [40] |